Connect with us

Technology

CME Group FX Futures and FX Link Reach All-Time Volume Records

Published

on

CHICAGO and LONDON, June 18, 2024 /PRNewswire/ — CME Group, the world’s leading derivatives marketplace, today announced its foreign exchange (FX) futures reached an all-time single-day volume record of 3.26 million contracts (equivalent to $314B notional) on June 12. The previous record of 3.15 million contracts ($296B notional) was set on March 8, 2023.

In addition, FX Link, CME Group’s anonymous, all-to-all spot-futures spread trading tool reached a single-day volume record of 113,662 contracts ($10.5B notional ) on June 12, which represents a 37% increase over the previous record of 82,900 contracts ($7.2B notional), set on June 16, 2022. Year-to-date, FX Link volumes are up over 52% versus the same period in 2023.

“Achieving two all-time volume records on June 12, is a significant milestone for CME Group FX products and is testament to the continued growth that we have seen in client segments, currency pairs and overall liquidity over many months,” said Paul Houston, Global Head of FX Products, CME Group. “FX Link will play a crucial role in our new CME FX Spot+ marketplace as we prepare for client testing in the second half of 2024. The improved liquidity, tighter spreads and increasing client participation builds an even stronger foundation for delivering value to market participants in the future.”

“We are pleased to see the continued growth in CME Group FX futures and FX Link as complementary sources of liquidity to the OTC market and as mechanisms to help automate the trading of products like FX swaps,” said Shuo Wu, Global Head of Forward eTrading, Deutsche Bank. “Deutsche Bank is a major liquidity provider to this marketplace as part of our market-leading portfolio of electronic trading products.”

“Record levels of listed FX volume are a clear indication of the rapidly evolving interplay of OTC and cleared FX futures liquidity. In particular, the use case of Exchange for Related Position (EFRP)  amongst institutional clients continues to resonate across hedge funds and asset managers alike,” said Richard Condon, Head of FX, Commodity and EM Institutional Sales, North America, BNP Paribas.  “Participants point toward the benefit of pairing the familiarity, breadth and relationship pricing of bilateral OTC execution strategies with the power of a centrally cleared instrument.”

FX Link provides a transparent central limit order book on CME Globex for trading spreads between OTC FX spot and CME Group FX futures, seamlessly connecting the two markets. Today, there are nine major FX prime brokers live, with credit lines in place with major bank FX house entities, along with integrated post-trade messaging provided by Traiana, RTN and IHS Markit.

FX Link spreads are listed with and subject to the rules of CME. For more information on FX Link, please visit www.cmegroup.com/trading/fx/fx-link.

For more information on CME Group FX products, go to www.cmegroup.com/fx

As the world’s leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals.  The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform.  In addition, it operates one of the world’s leading central counterparty clearing providers, CME Clearing. 

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc.  CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC (“S&P DJI”). “S&P®”, “S&P 500®”, “SPY®”, “SPX®”, US 500 and The 500 are trademarks of Standard & Poor’s Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.

CME-G

View original content:https://www.prnewswire.com/news-releases/cme-group-fx-futures-and-fx-link-reach-all-time-volume-records-302174808.html

SOURCE CME Group

Continue Reading

Technology

Innovative Immunology Biotech Windward Bio Lists on Nasdaq

Published

on

By

SHANGHAI, Nov. 14, 2026 /PRNewswire/ — Windward Bio, a portfolio company of Qiming Venture Partners and a clinical-stage biotechnology company, successfully listed on Nasdaq on November 13, 2026. Windward Bio (Nasdaq: WWB) priced its IPO at $17.00 per share. Its shares closed at $28.50 on the first trading day, up 68% from the IPO price, giving the company a market capitalization of approximately $1.69 billion. This is Qiming Venture Partners’ 11th IPO in 2026.

Qiming Venture Partners invested in Windward Bio’s inaugural Series A financing in 2025 and continued to support the company in its Series B financing in 2026. Qiming also participated in this IPO financing round.

Windward Bio was founded in 2024 with a mission to transform the treatment paradigm for patients living with chronic inflammatory diseases through the development of differentiated biologic therapies targeting clinically validated disease pathways. Led by a team with extensive expertise across discovery, development, and commercialization, Windward Bio is advancing a pipeline of ultra-long-acting antibody medicines to improve clinical outcomes, reduce treatment burden and expand treatment options for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.

Windward Bio’s lead program, WIN378, is a potentially novel anti-TSLP monoclonal antibody engineered for improved potency and extended half-life. WIN378 is currently being evaluated in POLARIS-1, a Phase 2/3 study in severe uncontrolled asthma, and SIRIUS, a Phase 2 study in COPD. The company’s pipeline also includes WIN027, a clinical-stage, long-acting bispecific antibody targeting TSLP and IL-13 with potential applications across multiple inflammatory and immunological diseases. Windward Bio holds exclusive global rights (excluding Greater China and certain Asian countries) to WIN378 through a licensing agreement with Kelun-Biotech and Harbour BioMed, and has separately licensed WIN027 from Qyuns Therapeutics.

“Qiming Venture Partners invests in differentiated, globally competitive biotech innovation designed to address significant unmet needs for patients, and Windward Bio exemplifies this approach. We believe novel, long-acting biologics will reshape the treatment of severe chronic respiratory and skin diseases, and that WIN378 and WIN027 have the potential to expand and meaningfully improve the treatment options available to patients. In the hands of Luca and his team, with their expertise and proven track record, Windward is well-positioned to deliver on this potential, and we look forward to supporting the company through its next phase of growth,” said Alexander Sinclair Wilson, Principal at Qiming Venture Partners.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 630 fast-growing and innovative companies. Over 290 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 110 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.AI, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others.

 

View original content:https://www.prnewswire.com/news-releases/innovative-immunology-biotech-windward-bio-lists-on-nasdaq-302939481.html

SOURCE Qiming Venture Partners

Continue Reading

Technology

WeFetch AI Corp. Is the New Name of GreenCore Solutions Corp.

Published

on

By

gtinfetch.ai, WeFetch.ai’s lead product, removes the guess from artificial intelligence (AI) shopping: the right barcode, and signed proof of it.

VANCOUVER, BC and LONDON, Nov. 13, 2026 /PRNewswire/ — WeFetch AI Corp., the artificial intelligence (AI) shopping company formerly named GreenCore Solutions Corp., has completed its change of name. The Registrar of Companies for British Columbia issued the Certificate of Change of Name on November 13, 2026.

One Answer for Every Barcode

An AI agent picks a product in words. The same words can match a dozen barcodes: the right brand in the wrong size, last year’s pack, a look-alike from another maker. When the agent guesses, the shopper gets the wrong product, the brand loses a sale it had already won, and the retailer pays for the return.

The Company’s lead product, gtinfetch.ai, removes the guess. It answers for 84,810,515 barcodes from 376,271 makers across 3,520,471 points of sale. An AI agent sends a barcode and gets a firm answer: verified, not verified or unknown, with the sources behind it.

Who it matters to:

The shopper gets the product they asked for.The brand keeps the sale the AI already gave it.The retailer does not pay for a wrong order.

A Signed Receipt of Every Check

When an AI agent buys on a shopper’s behalf, someone has to be able to show it bought the right product. Today nobody can: the agent’s choice leaves no record. gtinfetch.ai gives the agent a signed receipt of the check, written at rco.wefetch.ai and open to public verification. The retailer, the brand and the auditor can each see what was checked, when, and what the answer was. The mark is “Barcode verified”.

Three Regions, One Record

The full record now answers from France, Singapore and the United States. Every barcode also has its own free public page at gtinfetch.ai. The three regions are where AI shopping starts. Singapore has the highest consumer use of generative AI in Asia, at 64.3% of working-age people. France stands at 49.6% and the United States at 33.0%, against 18.8% worldwide. (Source: Microsoft AI Diffusion Report, Q2 2026.) They are also the home markets of the AI that shoppers ask: ChatGPT and Claude in the United States, Mistral in France, and Singapore among the top countries in the world for Claude use per head. (Source: Anthropic Economic Index.)

What we built

WeFetch.ai, the barcode fetch system for AI agents. It answers for 84 million products in 70 countries, with 3.5 million points of sale on its own record, and includes:

triggerfetch for brands;shopfetch for shoppers;matchfetch for AI agents;gtinfetch, the record itself.

It is AI native, and works with ChatGPT, Claude, Gemini, Grok, Mistral, Perplexity and Muse. Every answer is signed.

“Words were the first generation of AI answers. Barcodes are agentic commerce,” said Matthew Keddy, Chief Executive Officer of WeFetch AI Corp. “Every AI agent that moves from search results to shopping needs barcode precision. wefetch has it, signed, in three regions.”

The market: Gartner forecasts $2.7 trillion in AI spending in 2026. McKinsey projects that AI agents will orchestrate $3 trillion to $5 trillion in global commerce by 2030, up to $1 trillion of it in US retail. Every one of those AI agent purchases needs the right barcode.

About WeFetch AI Corp.

WeFetch AI Corp. develops AI software products for AI shopping, retail, grocery and fast-moving consumer goods (FMCG). Its lead product, gtinfetch.ai, is the AI agentic shopping barcode engine: 84 million barcodes, answered for the agents of seven AI labs. WeFetch is headquartered in Vancouver, Canada, with sales offices in London, UK. Please visit: wefetch.ai

View original content:https://www.prnewswire.com/news-releases/wefetch-ai-corp-is-the-new-name-of-greencore-solutions-corp-302939459.html

SOURCE Greencore Solutions Corp.

Continue Reading

Technology

/C O R R E C T I O N – BTQ Technologies Corp./

Published

on

By

In the news release, BTQ Technologies to Host Live Webinar on Q3 2026 Financial Results and General Corporate Update, issued Nov. 13, 2026 by BTQ Technologies Corp. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows:

BTQ Technologies to Host Live Webinar on Q3 2026 Financial Results and General Corporate Update

VANCOUVER, BC, Nov. 13, 2026 /PRNewswire/ — BTQ Technologies Corp. (“BTQ” or the “Company”) (Nasdaq: BTQ) (CBOE CA: BTQ),  a global technology company building the trust infrastructure for the quantum era, is pleased to announce that it will hold a shareholder call on Friday, November 17, 2026, at 11:00 a.m. EST to discuss its quarterly financial results and provide a general corporate update. The call will follow the release of the Company’s Q3 2026 financial statements, which will be issued after market close on Monday, November 16, 2026.

IMPORTANT – To register for the webcast see below:

When: November 17, 2026
Time: 11:00 AM Eastern Time
Topic: BTQ Technologies Shareholder Call to Discuss Q3 2026 Financial Results and Corporate Update

Register in advance for this webinar:
https://us06web.zoom.us/webinar/register/WN_n6WGI3lERpCZcA63pWQWVQ 

After registering, you will receive a confirmation email containing information about joining the webinar.

About BTQ
BTQ Technologies Corp. (Nasdaq: BTQ | Cboe CA: BTQ) is a quantum technology company focused on accelerating the transition from classical networks to the quantum internet. Backed by a broad patent portfolio and deep technical expertise, BTQ is developing a full-stack, neutral-atom quantum computing platform spanning hardware, middleware, and post-quantum security solutions for finance, telecommunications, logistics, life sciences, and defense.

Connect with BTQ: Website | LinkedIn | X/Twitter

ON BEHALF OF THE BOARD OF DIRECTORS
Olivier Roussy Newton
CEO, Chairman

Neither Cboe Canada nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

Certain statements herein contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Such forward-looking statements or information include but are not limited to statements or information with respect to the business plans of the Company, including with respect to its research partnerships, and anticipated markets in which the Company may be listing its common shares. Forward-looking statements or information often can be identified by the use of words such as “anticipate”, “intend”, “expect”, “plan” or “may” and the variations of these words are intended to identify forward-looking statements and information.

The Company has made numerous assumptions including among other things, assumptions about general business and economic conditions, the development of post-quantum algorithms and quantum vulnerabilities, and the quantum computing industry generally. The foregoing list of assumptions is not exhaustive.

Although management of the Company believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that forward-looking statements or information herein will prove to be accurate. Forward-looking statements and information are based on assumptions and involve known and unknown risks which may cause actual results to be materially different from any future results, expressed or implied, by such forward-looking statements or information. These factors include risks relating to: the availability of financing for the Company; business and economic conditions in the post-quantum and encryption computing industries generally; the speculative nature of the Company’s research and development programs; the supply and demand for labour and technological post-quantum and encryption technology; unanticipated events related to regulatory and licensing matters and environmental matters; changes in general economic conditions or conditions in the financial markets; changes in laws (including regulations respecting blockchains); risks related to the direct and indirect impact of COVID-19 including, but not limited to, its impact on general economic conditions, the ability to obtain financing as required, and causing potential delays to research and development activities; and other risk factors as detailed from time to time. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Correction: An earlier version of this release incorrectly [describe the update briefly].

View original content to download multimedia:https://www.prnewswire.com/news-releases/btq-technologies-to-host-live-webinar-on-q3-2026-financial-results-and-general-corporate-update-302939440.html

SOURCE BTQ Technologies Corp.

Continue Reading

Trending